Lycorine and its derivatives for anticancer drug design.
about
A Conserved Inhibitory Mechanism of a Lycorine Derivative against Enterovirus and Hepatitis C VirusLycorine sensitizes CD40 ligand-protected chronic lymphocytic leukemia cells to bezafibrate- and medroxyprogesterone acetate-induced apoptosis but dasatanib does not overcome reported CD40-mediated drug resistance.Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replicationIn search of a cytostatic agent derived from the alkaloid lycorine: synthesis and growth inhibitory properties of lycorine derivativesIdentification and differential regulation of microRNAs in response to methyl jasmonate treatment in Lycoris aurea by deep sequencing.Selection and Validation of Appropriate Reference Genes for Quantitative Real-Time PCR Analysis of Gene Expression in Lycoris aureaConvergent Synthesis of Diverse Nitrogen Heterocycles via Rh(III)-Catalyzed C-H Conjugate Addition/Cyclization Reactions.Amaryllidaceae alkaloids: Absolute configuration and biological activity.Metal-Catalyzed Asymmetric Michael Addition in Natural Product Synthesis.Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry.Anti-dengue-virus activity and structure-activity relationship studies of lycorine derivatives.5,10b-Ethanophenanthridine amaryllidaceae alkaloids inspire the discovery of novel bicyclic ring systems with activity against drug resistant cancer cellsUngeremine effectively targets mammalian as well as bacterial type I and type II topoisomerases.Alkaloids isolated from natural herbs as the anticancer agents.Synthetic analogues of the montanine-type alkaloids with activity against apoptosis-resistant cancer cells.Lycorine inhibits breast cancer growth and metastasis via inducing apoptosis and blocking Src/FAK-involved pathway.
P2860
Q26700115-8917C6E2-F3CE-428A-B328-4F1DD5B3428AQ34255124-791F709A-B9EE-44C3-857D-F4061E4C6006Q35540385-14B37663-4639-4FB3-8C0A-9AE8827698C7Q36057981-AB2199A4-4744-4F17-AA97-CB328A377F36Q36159822-619BAE64-D0BF-4B31-9135-963142E3E325Q36832463-58D3DFEB-F05F-4100-AFBF-563ECC904D99Q37152019-74B7087E-AD25-480D-8165-F70B27C257AEQ38947527-D79E4FBE-9A46-4C54-9F6E-3D0748B5438FQ39043176-9613FD4D-D7B7-4583-BD66-6EA12E83738FQ39317009-657B1564-32F0-4519-AD09-C7C85F17612AQ40216611-A03E240F-566A-4255-A68C-1DB1F42D34DFQ41744145-D320AD96-B8C2-41DC-9723-E539B5631DEFQ42082687-9432C562-2FEF-4FAF-978F-7C6160A5DE40Q42324855-CC28C92C-BE7F-4DD5-A7C5-C4B9B51B1C0FQ50154429-FEAB5DE0-442A-4A31-A08E-D253DB88B939Q50866048-6E907648-F9AC-408E-AD55-A2A28B1643EF
P2860
Lycorine and its derivatives for anticancer drug design.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lycorine and its derivatives for anticancer drug design.
@en
Lycorine and its derivatives for anticancer drug design.
@nl
type
label
Lycorine and its derivatives for anticancer drug design.
@en
Lycorine and its derivatives for anticancer drug design.
@nl
prefLabel
Lycorine and its derivatives for anticancer drug design.
@en
Lycorine and its derivatives for anticancer drug design.
@nl
P2093
P1476
Lycorine and its derivatives for anticancer drug design
@en
P2093
A Kornienko
C Decaestecker
D Lamoral-Theys
P356
10.2174/138955710791112604
P577
2010-01-01T00:00:00Z